RNAQ SEC filings, in plain English
Everything Rainier Acquisition Corp has filed with the SEC that we hold — 16 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Rainier Acquisition Corp (RNAQ) reported the closing of its $10.00 per unit IPO and over-allotment option on September 2, 2026, generating $86,250,000 in gross proceeds placed in a trust account. The filing details the simultaneous private placement of 200,000 units to Sponsor Ravenna 7 LLC at $10.00 per unit and includes an audited balance sheet as of August 28, 2026. Why it matters: Investors should note that the full trust value is now established at $86,250,000, setting the baseline for redemption calculations and potential business combination targets, while the sponsor's additional capital commitment signals confidence in the deal structure.
What changed: Rainier Acquisition Corp (CIK 2147219) filed an 8-K on August 28, 2026, reporting the consummation of its initial public offering (IPO) on that date. The Company sold 7,500,000 Units at $10.00 per Unit, generating $75,000,000 in gross proceeds. Each Unit consists of one Class A ordinary share and one-quarter of a redeemable warrant exercisable at $11.50. Simultaneously, the Sponsor, Ravenna 7 LLC, purchased 194,375 Private Placement Units at $10.00 per unit for $1,943,750. A total of $75,000,000 was placed into a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company. The filing also details the appointment of Wing C. Lam and Chidozie Ugwumba to the Board of Directors, the adoption of the Second Amended and Restated Memorandum and Articles of Association, and the establishment of Audit, Compensation, and Nominating committees with specified independent directors. Why it matters: This filing confirms the successful completion of the SPAC's capital raise, establishing the initial trust value of $10 per public share ($75,000,000 total). It defines the redemption mechanics: shareholders may redeem shares if the Company does not complete a business combination within 24 months from the IPO closing (August 28, 2026), or upon certain amendments to the charter. The document sets the timeline for the initial business combination deadline as August 28, 2028, unless extended. It also identifies the key governance structure and sponsor commitments, including the Letter Agreement requiring the Sponsor and directors to vote in favor of the initial business combination or facilitate liquidation if no deal is completed.
What changed: Registration statement on Form S-1 for an initial public offering of 7,500,000 units (each unit consisting of one Class A ordinary share and one-quarter of a redeemable warrant) at $10.00 per unit, with an over-allotment option of 1,125,000 additional units, by Rainier Acquisition Corporation, a blank check company focused on life sciences. This is the initial filing of the S-1 registration statement, marking the first public disclosure of the SPAC's IPO terms. Key elements include: $75,000,000 trust account ($10.00 per unit), 24-month deadline to complete a business combination, sponsor Ravenna 7 LLC (affiliated with underwriter Chardan Capital Markets), 2,156,250 founder shares purchased for $25,000, private placement of 194,375 units at $10.00 each, target focus on life sciences companies, and various agreements including warrant agreement, registration rights, and indemnification. Why it matters: This filing provides investors with the complete set of terms for the SPAC's IPO, including redemption mechanics, sponsor compensation and resulting dilution, conflicts of interest (Chardan acts as both underwriter and has an economic interest in the sponsor), the composition and experience of the management team, and the financial condition of the SPAC (working capital deficit of $80,846 as of June 30, 2026, with going concern uncertainty). It also details the 24-month timeframe, the absence of a maximum redemption threshold, and the 15% limitation on redemption by any single beneficial owner. This is the foundational document for evaluating the investment.
What changed: Confidential draft registration statement (Form S-1) for a special purpose acquisition company (SPAC) initial public offering, including a preliminary prospectus. Initial filing of a new SPAC IPO registration. The company seeks to raise $75 million ($10.00 per unit) with a 24-month deadline to complete an initial business combination. No target has been identified. Sponsor purchased founder shares at ~$0.01159 per share. Terms include a 15% redemption cap on public shares, deferred underwriting fees, and a conflict-of-interest qualified independent underwriter (B. Riley). Why it matters: Sets the structural and timeline terms for investors: $10.00 per share trust initially, 24-month completion window, life sciences focus, sponsor with Chardan affiliation, substantial dilution from founder shares, and redemption mechanics with a 15% cap on redemptions if shareholder vote is used.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.